InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,584.54
(
-0.88%
)
US TECH 100
19,672.40
(
-0.02%
)
Dow Jones
39,753.75
(
0.08%
)
Brent Oil
85.61
(
0.58%
)
Bitcoin
57,178.74
(
-0.30%
)
Post# of 514
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

MABMAN8

Send PM Follow Ignore
Followers 1
Posts 489
Boards Moderated 0
Alias Born 04/17/2011

MABMAN8

Re: spidaman post# 171

Sunday, 04/14/2013 5:41:17 PM

Sunday, April 14, 2013 5:41:17 PM

Post# of 514
It depends on how you define "short-term". The Phase 3 results from the eprat lupus trials will blow this stock up. It's the only therapy to show benefit in Phase 2 (BENLYSTA did not). It will represent a major upgrade to the BENLYSTA dud... Rheumatologists already love B-cell depletion therapy. The anti-CD22 approach offers a deviation from the anti-CD20 approach.

EULAR is in June & ACR is in November... I would not be surprised to start seeing some of the data presented at these meetings... If you are not leveraged in, you may miss the window to really capitalize.

$10 is conservative for this stock over the next 12 months... $22-$25 is quite possible
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up